Investors & Press

Agendia is a privately owned company that has successfully raised funds to develop and market its portfolio of FFPE-based genomic diagnostic products for breast cancer. The Company believes it is well positioned for growth within the shifting paradigm of cancer treatment towards personalized medicine through precision science and the increased market demand for molecular diagnostics.  With a pipeline of genomic products in development, the company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and the MINDACT trials.

Original shareholders include the founders of Agendia and Stichting Fondsen Nederland that originated from the Netherlands Cancer Institute.